CONJUGATE TO STIMULATE IMMUNE RESPONSE AGAINST A TARGET CELL, METHOD TO TREAT MALIGNANT TUMORS IN MAMMALIANS Russian patent published in 2002 - IPC

FIELD: medicine, immunology, oncology. SUBSTANCE: the suggested conjugate contains a monoclonal antibody C215, a monoclonal antibody C242 or their antigen-binding fragments and Staphylococcal enterotoxin A (SEA). The latter contains the mutation D227 A, reveals decreased capacity for binding to MHC antigens of type II against native SEA, keeps the capacity for binding to Vβ T-cellular receptor. Conjugate in question is obtained due to recombinant techniques. Treatment of mammalian malignant tumors is conducted due to injection of therapeutically efficient amount of the conjugate suggested. EFFECT: higher capacity to bind to MHC antigens of type II in mammalian cells. 2 cl, 7 dwg, 3 tbl